Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cells

Kidney International

Volumn 64, Issue 2, 2003, Pages 421-430

  Meinhardt, Udo ^b   Eblé, Andrée ^b   Besson, Amélie ^b   Strasburger, Christian J ^b   Sraer, Jean Daniel ^b   Mullis, Primus E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

Growth hormone; Growth hormone binding protein; Growth hormone receptor; Mesangial cells; Transcription

Indexed keywords

COLLAGEN; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ARTICLE; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 0038441761     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00117.x     Document Type: Article

References (61)

1. FELD S, HIRSCHBERG R: Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 17:423-480, 1996
2. PRESS M: Growth hormone and metabolism. Diabetes Metab Rev 4:391-414, 1988
3. FLYVBJERG A, FRYSTYK J, OSTERBY R, ORSKOV H: Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am J Physiol 262:E956-E962, 1992
4. ROELFSEMA V, CLARK RG: The growth hormone and insulin-like growth factor axis: Its manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol 12:1297-1306, 2001
5. ELLIOT SJ, STRIKER LJ, HATTORI M, et al: Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factor-I. Endocrinology 133:1783-1788, 1993
6. TACK I, ELLIOT SJ, POTIER M, et al: Autocrine activation of the IGF-I signalling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes 51:182-188, 2002
7. DOUBLIER S, SEURIN D, FOUQUERAY B, et al: Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1, Kidney Int 57:2299-2397, 2000
8. ESPOSITO C, LIU ZH, STRIKER GE, et al: Inhibition of diabetic nephropathy by GH antagonist: A molecular analysis. Kidney Int 50:506-514, 1996
9. SEGEV Y, LANDAU D, RASCH R, et al: Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol 10:2374-2381, 1999
10. BELLUSH LL, DOUBLIER S, HOLLAND AN, et al: Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 141:163-168, 2000
11. FLYVBJERG A: Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int 52 (Suppl 60):S12-S19, 1997
12. FLYVBJERG A, BENNETT WF, RASCH R, et al: Inhibitory effect of growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 48:377-382, 1999
13. DOI T, STRIKER LJ, QUAIFE C, et al: Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone ad growth hormone releasing factor but not those expressing insulin like growth-factor-1. Am J Pathol 131:398-403, 1988
14. YANG CW, STRIKER LJ, PESCE C, et al: Glomerulosclerosis and body growth are mediated by different portions of bovine growth hormone: Studies on transgenic mice. Lab Invest 68:62-70, 1993
15. GOYA RG, CASTELLETTO L, SOSA YE: Plasma levels of growth hormone correlate with the severity of pathologic changes in the renal structure of aging rats. Lab Invest 64:29-43, 1991
16. TAKAI M, IZUMINO K, ODA Y, et al: Focal segmental glomerulosclerosis associated with acromegaly. Clin Nephrol 56:75-77, 2001
17. YOSHIDA H, AKIKUSA B, SAEKI N, et al: Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: Report of a rare clinical case. Am J Kidney Dis 33:1158-1163, 1999
18. FLYVBJERG A, BENNETT WF, RASCH R, et al: Compensatory renal growth in uninephrectomized adult mice is growth hormone dependent. Kidney Int 56:2048-2054, 1999
19. YOSHIDA H, MITARAI T, KITAMURA M, et al: The effect of selective growth hormone defect in the progression of glomerulosclerosis. Am J Kidney Dis 23:302-312, 1994
20. MENON RK, STEPHAN DA, RAO RH, et al: Tissue-specific regulation of the growth hormone receptor gene in streptozotocin-induced diabetes in the rat. J Endocrinol 142:453-462, 1994
21. CHEN WY, WIGHT DC, METHA BV, et al: Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 87:5061-5065, 1990
22. CHEN NY, CHEN WY, BELLUSH L, et al: Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 136:660-667, 1995
23. DOI T, STRIKER LJ, KIMATA K. et al: Glomerulosclerosis in mice transgenic for growth hormone. Increased mesangial extracellular matrix is correlated with kidney mRNA levels. J Exp Med 173: 1287-1290, 1991
24. FELD S, HIRSCHBERG R, ARTISHEVSKY A, et al: Insulin-like growth factor-I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int 48:45-51, 1995
25. STEWART TA, CLIFT S, PITTS-MEEK S, et al: An evaluation of the function of the 22-kilodalton (kDa), the 20-kDa, and the N-terminal polypeptide forms of human growth hormone using transgenic mice. Endocrinology 130:405-414, 1992
26. SRAER JD, DELARUE F, HAGEGE J, et al: Stable cell lines of T-SV40 immortalized human glomerular mesangial cell. Kidney Int 49:267-270, 1996
27. BARASH I, CROMLISH W, POSNER BI: Prolactin (PRL) receptor induction in cultured rat hepatocytes: dual regulation by PRL and growth hormone. Endocrinology 122:1151-1158, 1988
28. TRAINER PJ, DRAKE WM, KATZNELSON L, et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1211, 2000
29. MULLIS PE, HOLL RW, LUND T, et al: Regulation of human growth hormone-binding protein production by human growth hormone in a hepatoma cell line. Mol Cell Endocrinol 111:181-190, 1995
30. LOBIE PE, MERTANI H, NOREL G, et al: Receptor mediated nuclear translocation of growth hormone. J Biol Chem 269:21330-21339, 1994
31. CHOMCZYNSKi P, SACCHI N: Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
32. MARTINI JF, VILLARES SM, NAGANO M, et al: Quantitative analysis by polymerase chain reaction of growth hormone receptor gene expression in human liver and muscle. Endocrinology 136:1355-1360, 1995
33. LEUNG DW, SPENCER SA, CACHIACES G, et al: Growth hormone receptor and serum binding protein: Purification, cloning and expression. Nature 330:537-543, 1987
34. HOLL RW, SIEGLER B, SCHERBAUM WA, HEINZE E: The serum growth hormone-binding protein is reduced in young patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 76:165-167, 1993
35. HOLL RW, SNEHOTTA R, SIEGLER B, et al: Binding protein for human growth hormone: Effects of age and weight. Horm Res 35:190-197, 1991
36. BAUMANN G, STOLAR MW, AMBURN K, et al: A specific growth hormone-binding protein in human plasma: Initial characterization. J Clin Endocrinol Metab 62:134-141, 1986
37. BAUMANN G, SHAW MA: A second lower affinity growth hormone binding protein in human plasma. J Clin Endocrinol Metab 70:680-686, 1990
38. CLEMMONS DR: Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res 55(Suppl 2):73-79, 2001.
39. CHESTNUT RE, QUARMBY V: Evaluation of total IGF-I assay methods using samples from type I and type II diabetic patients. J Immunol Methods 259:11-24, 2002
40. DOI SQ, RASAIAH S, TACK I, et al: Low-protein diet suppresses serum insulin-like growth factor-I and decelerates the progression of growth-hormone-induced glomerulosclerosis. Am J Nephrol 21:331-339, 2001
41. LIU ZH, STRIKER LJ, PHILLIPS C, et al: Growth hormone expression is required for the development of diabetic glomerulosclerosis in mice. Kidney Int 48(Suppl 51):S37-S38, 1995
42. MENÉ P, SIMONSON MS, DUNN MJ: Physiology of the mesangial cell. Physiol Rev 69:1347-1424, 1989
43. BAUMANN G: Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 12:424-449, 1991
44. LEWIS UJ, SINHA YN, HARO LS: Variant forms and fragments of human growth hormone in serum. Acta Paediatr 399:29-31, 1994
45. JANSSON C, BOGUSZEWSKI CL, ROSBERG S, et al: Growth hormone (GH) assays: Influences of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem 43:950-956, 1997
46. BOGUSZEWSKI CL, HYNSJÖ L, JOHANNSSON G, et al: 22-kDa growth hormone exclusion assay: A new approach to measurement of non-22kDa growth hormone isoforms in human blood. Eur J Endocrinol 135:573-582, 1996
47. LEUNG DW, SPENCER SA, CACHIANES G, et al: Growth hormone receptor and serum binding protein: Purification, cloning and expression. Nature 330:537-543, 1987
48. BAUMANN G, STOLAR MW, AMBURN K, et al: A specific growth hormone-binding protein in human plasma: Initial characterization. J Clin Endocrinol Metab 62:134-141, 1986
49. HERINGTON AC, TIONG TS, YMER SI: Serum binding proteins for growth hormone: Origins, regulation of gene expression and possible roles. Acta Paediatr Scand 379:61-69, 1991
50. YMER SI, STEVENSON JL, HERINGTON AC: Identification of a rabbit liver cytosolic binding protein for human growth hormone. Biochem J 221:617-622, 1984
51. SMITH WC, TALAMANTES FJ: Identification and characterization of a heterogeneous population of growth hormone receptors in mouse hepatic membranes. J Biol Chem 262:2213-2219, 1987
52. AMIT T, BARKEY RJ, BICK T, et al: Identification of growth hormone binding protein in rat serum. Mol Cell Endocrinol 70:197-202, 1990
53. DAUGHADAY WH, TRIVEDI B, LAUTERIO T: Program of the 69th Annual Meeting of the Endocrine Society Meeting, Indianapolis, Indiana, 97, 1987
54. SMITH WC, KUNIYOSHI J, TALAMANTES F: Mouse serum growth hormone binding protein has GH receptor extracellular and substituted transmembrane domains. Mol Endocrinol 2:984-990, 1989
55. BAUMBACH WR, HORNER DL, LOGAN JS: The growth hormone-binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor. Genes Dev 3:1199-1205, 1989
56. CONTE F, SALLES JP, RAYNAL P, et al: Identification of a region critical for proteolysis of the human growth hormone receptor. Biochem Biophys Res Commun 290:851-857, 2002
57. AMIT T, HOCHBERG Z, YOGEV-FALACH M, et al: Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: Proposed mechanism of activation of growth hormone-binding protein secretase. J Endocrinol 169:397-407, 2001
58. GUAN R, ZHANG Y, JIANG J, et al: Phorbol ester- and growth factor-induced growth hormone (GH) receptor proteolysis and GH-binding protein shedding: relationship to GH receptor down-regulation. Endocrinology 142:1137-1147, 2001
59. TRAINER PJ, DRAKE WM, KATZNELSON L, et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1211, 2000
60. VAN NECK JW, DITS NFJ, HOPPENBROUWERS IA, et al: Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice. J Endocrinol 167:295-303, 2000
61. LUPIA E, ELLIOT SJ, LENZ O, et al: IGF-I decreases collagen degradation in diabetic NOD mesangial cells. Implications for diabetic nephropathy. Diabetes 48:1638-1644, 1999